Trinity Biotech PLC
NASDAQ:TRIB

Watchlist Manager
Trinity Biotech PLC Logo
Trinity Biotech PLC
NASDAQ:TRIB
Watchlist
Price: 0.6645 USD -5.74% Market Closed
Market Cap: $12.6m

Trinity Biotech PLC
Accrued Liabilities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Trinity Biotech PLC
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Trinity Biotech PLC
NASDAQ:TRIB
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Medtronic PLC
NYSE:MDT
Accrued Liabilities
$5.7B
CAGR 3-Years
0%
CAGR 5-Years
-3%
CAGR 10-Years
3%
STERIS plc
NYSE:STE
Accrued Liabilities
$487.2m
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
15%
No Stocks Found

Trinity Biotech PLC
Glance View

Market Cap
12.6m USD
Industry
Health Care

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The company is headquartered in Bray, Wicklow. The firm's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. The company operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business.

TRIB Intrinsic Value
2.5772 USD
Undervaluation 74%
Intrinsic Value
Price $0.6645

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett